Altshuler, L.L., Sugar, C.A., McElroy, S.L., et al. (2017). Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. American Journal of Psychiatry, 174, 266–76.Google Scholar

Amsterdam, J.D., Shults, J. (2010). Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. American Journal of Psychiatry, 167, 792–800.CrossRefGoogle ScholarPubMed

Amsterdam, J.D., Shults, J.. (2008). Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. Journal of Clinical Psychopharmacology, 28, 171–81.CrossRefGoogle ScholarPubMed

Amsterdam, J.D., Lorenzo-Luaces, L., Soeller, I., et al. (2015). Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. Journal of Affective Disorders, 185, 31–7.Google Scholar

Amsterdam, J.D., Lorenzo-Luaces, L., Soeller, I., et al. (2016). Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. British Journal of Psychiatry, 208, 359–65.Google Scholar

Angst, J. (1998). The emerging epidemiology of hypomania and bipolar II disorder. Journal of Affective Disorders, 50, 143–51.CrossRefGoogle ScholarPubMed

Baron, M., Gershon, E.S., Rudy, V., et al. (1975). Lithium carbonate response in depression: prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Archives of General Psychiatry, 32, 1107–11.CrossRefGoogle ScholarPubMed

Bond, D.J., Lam, R.W., Yatham, L.N. (2010). Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. Journal of Affective Disorders, 124, 228–34.Google Scholar

Bowden, C.L., Singh, V., Weisler, R., et al. (2012). Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatrica Scandinavica, 126, 342–50.Google Scholar

Calabrese, J.R., Huffman, R.F., White, R.L., et al. (2008). Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders, 10, 323–33.Google Scholar

Calabrese, J.R., Shelton, M.D., Rapport, D.J., et al. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry, 162, 2152–61.CrossRefGoogle ScholarPubMed

Calabrese, J.R., Suppes, T., Bowden, C.L., et al. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry, 61, 841–50.Google Scholar

Carney, S.M., and Goodwin, G.M. (2005). Lithium – a continuing story in the treatment of bipolar disorder. Acta Psychiatrica Scandinavica.Supplementum, 426, 7–12.Google Scholar

Datto, C., Pottorf, W.J., Feeley, L., et al. (2016). Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Annals of General Psychiatry, 15, 9.CrossRefGoogle Scholar

Donnelly, E.F., Goodwin, F.K., Waldman, I.N., and Murphy, D.L. (1978). Prediction of antidepressant responses to lithium. American Journal of Psychiatry, 135, 552–6.Google ScholarPubMed

Dunner, D.L., Stallone, F., Fieve, R.R. (1982). Prophylaxis with lithium carbonate: an update. Archives of General Psychiatry, 39, 1344–5.Google Scholar

El-Mallakh, R.S., Salem, M.R., Chopra, A., et al. (2010). A blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects. Annals of Clinical Psychiatry, 22, 3–8.Google ScholarPubMed

Fieve, R.R., Kumbaraci, T., Dunner, D.L. (1976). Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. American Journal of Psychiatry, 139, 747–52.Google Scholar

Frankenburg, F.R., and Zanarini, M.C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442–6.Google Scholar

Frye, M.A., Ketter, T.A., Kinbrell, T.A., et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology, 20, 607–14.CrossRefGoogle ScholarPubMed

Geddes, J.R., Calabrese, J.R., Goodwin, G.M. (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 194, 4–9.Google Scholar

Geddes, J.R., Gardiner, A., Rendell, J., et al. (2016). Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2×2 factorial randomised trial. Lancet Psychiatry, 3, 31–9.Google Scholar

Goodwin, F.K., Fireman, B., Simon, G.E., et al. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. Journal of the American Medical Association, 290, 1467–73.Google ScholarPubMed

Goodwin, F.K., Murphy, D.L., Bunney, W.E. Jr. (1969). Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. Archives of General Psychiatry, 21, 486–96.Google Scholar

Goodwin, F.K., Murphy, D.L., Dunner, D.L., Bunney, WE Jr. (1972). Lithium response in unipolar versus bipolar depression. American Journal of Psychiatry, 129, 44–7.Google Scholar

Greil, W., Kleindienst, N. (1999). Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. International Clinical Psychopharmacololgy, 14, 283–5.Google Scholar

Grunze, H.C. (2010). Anticonvulsants in bipolar disorder. Journal of Mental Health, 19, 127–41.CrossRefGoogle ScholarPubMed

Jacobsen, F. M. (1993). Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Journal of Clinical Psychiatry, 54, 229–34.Google ScholarPubMed

Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59, 530–7.Google Scholar

Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60, 261–9.CrossRefGoogle ScholarPubMed

Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. (2005). Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322–30.Google Scholar

Judd, L.L., Akiskal, H.S., Schettler, P.J., et al. (2008). Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. Journal of Affective Disorders, 108, 49–58.CrossRefGoogle ScholarPubMed

Juruena, M.F., Ottoni, G.L., Machado-Vieira, R., et al. (2009). Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33, 94–9.Google Scholar

Kane, J.M., Quitkin, F.M., Rifkin, A., et al. (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry, 39, 1065–9.Google Scholar

Kupka, R.W., Altshuler, L.L., Nolen, W.A., et al. (2007). Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disorders, 9, 531–5.Google Scholar

Malhi, G.S., Mitchell, P.B., Berk, M., Goodwin, G. M. (2005). Mood stabilizers: a labile label. Acta Psychiatrica Scandinavica.Supplementum, 426, 5–6.CrossRefGoogle Scholar

McElroy, S.L., Martens, B.E., Creech, R.S., et al. (2010a). Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. Journal of Clinical Psychiatry, 71, 557–65.Google Scholar

McElroy, S.L., Weisler, R.H., Chang, W., et al. (2010b) A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry, 71, 163–74.Google Scholar

McIntyre, R.S., Mancini, D.A., McCann, S., et al. (2002). Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disorders, 4, 207–13.CrossRefGoogle ScholarPubMed

Merikangas, K.R., Akiskal, H.S., Angst, J., et al. (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Archives of General Psychiatry, 64, 543–52.Google Scholar

Muzina, D.J., Gao, K., Kemp, D.E., et al. (2011). Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 72, 813–19.Google ScholarPubMed

Nemeroff, C.B., Evans, D.L., Gyulai, L., et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–12.Google Scholar

Nierenberg, A.A., McElroy, S.L., Friedman, E.S., et al. (2016). Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. Journal of Clinical Psychiatry, 77, 90–9.Google ScholarPubMed

Pacchiarotti, I., Bond, DJ., Baldessarini, R.J., et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170, 1249–62.Google Scholar

Parikh, S.V., Hawke, L.D., Velyvis, V., et al. (2015). Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disorders, 17, 86–96.CrossRefGoogle ScholarPubMed

Parker, G., Tully, L., Olley, A., Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.CrossRefGoogle ScholarPubMed

Sachs, G.S., Collins, M.A., Altsguler, L.L., et al. (2001). Divalproex sodium versus placebo in the treatment of bipolar depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8.Google Scholar

Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., et al. (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356, 1711–22.CrossRefGoogle ScholarPubMed

Schaffer, A., Isometsa, E.T., Tondo, L., et al. (2015). Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the international society for bipolar disorders task force on suicide in bipolar disorder. Australian and New Zealand Journal of Psychiatry, 49, 785–802.Google Scholar

Singh, J., Chen, G., Canuso, C.M. (2012). Antipsychotics in the treatment of bipolar disorder. Handbook of Experimental Pharmacology, 212, 187–212.Google Scholar

Suppes, T., Marangell, L.B., Bernstein, I.H., et al. (2008). A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders, 111, 334–43.Google Scholar

Tondo, L., Baldessarini, R.J., Hennen, J., Floris, G. (1998). Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. American Journal of Psychiatry, 155, 638–45.Google Scholar

Unholzer, S., and Haen, E. (2015). Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine. Pharmacopsychiatry, 48, 211–14.Google ScholarPubMed

van der Loos, M.L., Mulder, P.G., Hartong, E.G., et al. (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 70, 223–31.Google Scholar

Yatham, L.N. (2005). Diagnosis and management of patients with bipolar II disorder. Journal of Clinical Psychiatry, 66 Suppl. 1, 13–17.Google ScholarPubMed

Yatham, L.N., Beaulieu, S., Schaffer, A., et al. (2016). Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Molecular Psychiatry, 21, 1050–6.Google Scholar

Young, A.H., Calabrese, J.R., Gustafsson, U., et al. (2013). Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International Journal of Bipolar Disorders, 1, 10.Google Scholar

Young, A.H., McElroy, S.L., Bauer, M., et al. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Journal of Clinical Psychiatry, 71, 150–62.Google Scholar

Young, A.H., McElroy, S.L., Olausson, B., et al. (2014). A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World Journal of Biological Psychiatry, 15, 96–112.Google Scholar

Young, L.T., Joffe, R.T., Robb, J.C., et al. (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American Journal of Psychiatry, 157, 124–6.Google Scholar

Young, L.T., Robb, J.C., Hasey, G.M., et al. (1999). Gabapentin as an adjunctive treatment in bipolar disorder. Journal of Affective Disorders, 55, 73–7.Google Scholar